4 months ago
On May 30, 2024, FDA Approves Bristol Myers Squibb’s Breyanzi for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) On May 30, 2024, Bristol Myers Squibb announced that the U...
4 months ago
**The Journey of an Indian Cancer Patient Seeking Treatment in China: Gratitude to Be Brought Back to India** patient story “Before coming to China for treatment, I was filled with worries...
4 months ago
Breyanzi Second Line is Effective in the Treatment of Relapsed or Refractory Large B-cell Lymphoma (r/r lbcl) In January 2022, Bristol Myers Squibb (BMS) announced the pre-specified interim analysi...
4 months ago
Breyanzi Label Expanded for the Third Time on May 31, 2024 On Thursday, May 31, 2024, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maral...
4 months ago
Breyanzi Indications Introduction to Breyanzi Product Name: Breyanzi Generic Name: Lisocabtagene Maraleucel (liso-cel) Target: CD19 Company: Bristol Myers Squibb (BMS), Juno Therapeutics First Appr...
4 months ago
On May 16, 2024, the U.S. FDA Granted Accelerated Approval for Expanded Indication of Breyanzi for Follicular Lymphoma On May 16, 2024, the U.S. Food and Drug Administration (FDA) announced acceler...
4 months ago
**Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!** Parkinson’s Disease **Breakthrough Research** ...
4 months ago
Breyanzi DLBCL Overview of FDA Approval of Breyanzi Breyanzi was approved by the U.S. FDA on February 5, 2021, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma ...
4 months ago
Breyanzi Company is Bristol Myers Squibb (abbreviated as BMY) Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy developed by the American pharmaceutical company Brist...
4 months ago
Breyanzi CD19 CAR-T Cells Immunotherapy Breyanzi Introduction In the ever-evolving landscape of cancer treatment, CAR-T (Chimeric Antigen Receptor T-cell) therapy has emerged as a game-changer, off...
4 months ago
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient Patient story Subtitle: Fighting for Love! A story of miraculous rebirth afte...
4 months ago
BMS Breyanzi FDA Approval History Breyanzi Introduction Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T cell (CAR-T) therapy, developed by Bristol Myers Squibb (BMS...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
